News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Osisko priced an upsized US$600m 9.25% senior secured note due 2031.
  • Proceeds will refinance the Appian project financing facility.
  • Proceeds will fund advancement of the Cariboo Gold Project in BC.
  • The notes are secured by first-priority liens on Osisko's assets and subsidiaries.
  • The 9.25% coupon reflects elevated financing cost for the company.
  • Deal advances Osisko's objective to become an intermediate gold producer.

Latest Articles

Disciplined Growth Acquisition Corporation Announces the Separate Trading of its Class A Ordinary Shares and Rights, Commencing July 17, 2026

Disciplined Growth Acquisition Corporation Announces the Separate Trading of its Class A Ordinary Shares and Rights, Commencing July 17, 2026

Disciplined Growth Acquisition Corporation announced that starting July 17, 2026, investors can separately trade its Class A ordinary shares and rights, which were part of the units sold in its IPO. The shares and rights will trade under the symbols DGAC and DGACR respectively, while units not separated will continue trading as DGACU. The company i…

H2O America to Report Second Quarter 2026 Financial Results on July 27

H2O America to Report Second Quarter 2026 Financial Results on July 27

H2O America, a national investor-owned water and wastewater utilities network, will report its Q2 2026 financial results post-market on July 27, followed by a conference call on July 28 to discuss the results and recent developments. The company emphasizes its commitment to delivering clean water to over 1.6 million people across the U.S. through i…

Amazon's AWS Re-Run: Ride the Next AI Infrastructure Leg

Amazon's AWS Re-Run: Ride the Next AI Infrastructure Leg

Amazon is repeating its AWS bet as it heads into the Q2 report cycle. With a $2.66T market cap, a P/E near 29x and EV/EBITDA around 17x, the stock offers a play on accelerating AI infrastructure demand. This trade sets a clear entry, stop and target with a mid-term (45 trading days) horizon to capture a re-rating if revenue and guidance tilt toward…

Writers Guild Files Suit to Halt Paramount's $110 Billion Deal, Saying It Would Weaken Competition for Screenwriters

Writers Guild Files Suit to Halt Paramount's $110 Billion Deal, Saying It Would Weaken Competition for Screenwriters

The Writers Guild of America has initiated a lawsuit seeking to block Paramount Global’s proposed $110 billion purchase of Warner Bros. Discovery, contending the transaction would unlawfully reduce competition for screenwriting services in film and television and harm writers’ wages and employment prospects. The move follows a separate challenge fr…

Elite Express Holding Inc. Reports Second Quarter 2026 Results

Elite Express Holding Inc. Reports Second Quarter 2026 Results

Elite Express Holding Inc. reported a 15.3% revenue increase to $726,829 in Q2 2026, driven by higher fixed revenues and an ISP agreement with FedEx. Gross profit improved significantly due to revenue growth outpacing costs. However, substantial increases in general and administrative expenses and a $2.15 million R&D investment caused net losses to…

Paylocity announces Q4 FY26 earnings conference call

Paylocity announces Q4 FY26 earnings conference call

Paylocity Holding Corporation announced its upcoming conference call to discuss fourth quarter and fiscal 2026 results, scheduled for August 4, 2026. The company provides cloud-based HR, Finance, and IT software solutions, promoting an integrated platform with AI-driven features to enhance workplace operations.

ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer

ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer

ORIC Pharmaceuticals announced the initiation of the global Phase 3 Himalayas-1 trial evaluating rinzimetostat in combination with Bayer's darolutamide (NUBEQA) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone. The trial will enroll approximately 600 patients across 25 countries to assess …